Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Med Chem ; 59(17): 8103-24, 2016 09 08.
Artigo em Inglês | MEDLINE | ID: mdl-27491023

RESUMO

Structure-activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogues of the irreversible pan-erbB inhibitor, canertinib. Cyclic amine bearing crotonamides were determined to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays. The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated. Several anilines were identified as providing potent, reversible pan-erbB inhibition. Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo. Quinazoline 54 and pyrido[3,4-d]pyrimidine 71 were identified as clearly superior to canertinib. Both compounds possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents, respectively. Pharmacokinetic comparison of compounds 54 and 71 across three species selected compound 54 as the preferred candidate. Compound 54 (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clinical evaluation.


Assuntos
Antineoplásicos/química , Receptores ErbB/antagonistas & inibidores , Morfolinas/química , Piridinas/química , Pirimidinas/química , Quinazolinas/química , Quinazolinonas/química , Administração Oral , Animais , Antineoplásicos/síntese química , Antineoplásicos/farmacocinética , Antineoplásicos/farmacologia , Cães , Xenoenxertos , Humanos , Injeções Intravenosas , Macaca fascicularis , Masculino , Camundongos Nus , Morfolinas/síntese química , Morfolinas/farmacocinética , Morfolinas/farmacologia , Transplante de Neoplasias , Fosforilação , Piridinas/síntese química , Piridinas/farmacocinética , Piridinas/farmacologia , Pirimidinas/síntese química , Pirimidinas/farmacocinética , Pirimidinas/farmacologia , Quinazolinas/síntese química , Quinazolinas/farmacocinética , Quinazolinas/farmacologia , Quinazolinonas/síntese química , Quinazolinonas/farmacocinética , Quinazolinonas/farmacologia , Ratos Sprague-Dawley , Estereoisomerismo , Relação Estrutura-Atividade
2.
Bioorg Med Chem ; 16(3): 1162-73, 2008 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-18024138

RESUMO

A series of 2- and 3-OH Nile red dyes was prepared in order to generate water-soluble probes that could be used to probe lipid binding to proteins. Various substitutions in positions 2-/3-, 6-, and 7-shifted wavelengths while maintaining the environmental sensitivity of Nile red. In order to increase the solubility of the dyes in aqueous solutions, we attached butyric acid groups to the 2- or 3-OH position. In addition, phenothiazine dyes, which exhibited particularly long excitation properties, were synthesized and tested for the first time. All dyes showed Stoke's shifts of 70-100 nm and changes in excitation and emission of over 100 nm, depending on the hydrophobicity of the environment. Binding studies with bovine serum albumin and the non-specific lipid transfer protein SCP2 revealed emission changes of more than 30 nm upon binding to the protein and a five-fold increase in emission intensity. Titration of the dye-loaded proteins with various lipids or drugs replaced the dye and thereby reversed the shift in wavelength intensity. This allowed us to estimate the lipid binding affinity of the investigated proteins. For SCP2, isothermal calorimetry (ITC) data verified the titration experiments. NMR titration experiments of SCP2 with Nile red 2-O-butyric acid (1a) revealed that the dye is bound within the lipid binding pocket and competes with lipid ligands for this binding site. These results give valuable insight into lipid and drug transport by proteins outside and inside cells.


Assuntos
Corantes Fluorescentes/química , Lipídeos/química , Preparações Farmacêuticas/química , Alquilação , Animais , Ácido Butírico/química , Calorimetria , Proteínas de Transporte/química , Bovinos , Corantes Fluorescentes/síntese química , Humanos , Modelos Moleculares , Estrutura Molecular , Soroalbumina Bovina/química , Titulometria
3.
J Med Chem ; 50(21): 5090-102, 2007 Oct 18.
Artigo em Inglês | MEDLINE | ID: mdl-17880056

RESUMO

A new series of MEK1 inhibitors, the 4-anilino-5-carboxamido-2-pyridones, were designed and synthesized using a combination of medicinal chemistry, computational chemistry, and structural elucidation. The effect of variation in the carboxamide side chain, substitution on the pyridone nitrogen, and replacement of the 4'-iodide were all investigated. This study afforded several compounds which were either equipotent or more potent than the clinical candidate CI-1040 (1) in an isolated enzyme assay, as well as murine colon carcinoma (C26) cells, as measured by suppression of phosphorylated ERK substrate. Most notably, pyridone 27 was found to be more potent than 1 in vitro and produced a 100% response rate at a lower dose than 1, when tested for in vivo efficacy in animals bearing C26 tumors.


Assuntos
Amidas/síntese química , Compostos de Anilina/síntese química , Antineoplásicos/síntese química , MAP Quinase Quinase 1/antagonistas & inibidores , MAP Quinase Quinase 2/antagonistas & inibidores , Piridonas/síntese química , Amidas/química , Amidas/farmacologia , Compostos de Anilina/química , Compostos de Anilina/farmacologia , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Benzamidas/farmacologia , Linhagem Celular Tumoral , Ensaios de Seleção de Medicamentos Antitumorais , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , MAP Quinase Quinase 1/química , MAP Quinase Quinase 2/química , Masculino , Camundongos , Modelos Moleculares , Transplante de Neoplasias , Fosforilação , Piridonas/química , Piridonas/farmacologia , Ratos , Relação Estrutura-Atividade
4.
J Med Chem ; 46(25): 5505-11, 2003 Dec 04.
Artigo em Inglês | MEDLINE | ID: mdl-14640558

RESUMO

Derivatives of the highly selective kappa-opioid receptor antagonist GNTI (2a) have been prepared. Binding and functional studies conducted on cloned human opioid receptors expressed in Chinese hamster ovarian (CHO) cells suggested that adding a benzyl or a substituted benzyl group to the guanidino moiety led, in general, to a retention of high kappa-affinity and antagonist potency. Disubstitution of the guanidino moiety led to reduced kappa-selectivity.


Assuntos
Guanidinas/síntese química , Morfinanos/síntese química , Receptores Opioides kappa/antagonistas & inibidores , Animais , Células CHO , Cricetinae , Guanidinas/química , Guanidinas/farmacologia , Humanos , Morfinanos/química , Morfinanos/farmacologia , Relação Estrutura-Atividade
5.
J Med Chem ; 46(2): 314-7, 2003 Jan 16.
Artigo em Inglês | MEDLINE | ID: mdl-12519069

RESUMO

The role of the side chain in 5'-substituted analogues of naltrindole has been further explored with the synthesis of series of amides, amidines, and ureas. Amidines (8, 13) had greatest selectivity for the kappa receptor, as predicted from consideration of the message-address concept. It was also found that an appropriately located carbonyl group, in ureas (10) and amides (7), led to retention of affinity and antagonist potency at the delta receptor.


Assuntos
Naltrexona/análogos & derivados , Naltrexona/síntese química , Antagonistas de Entorpecentes/síntese química , Receptores Opioides delta/antagonistas & inibidores , Receptores Opioides kappa/antagonistas & inibidores , Amidas/síntese química , Amidas/química , Amidas/farmacologia , Amidinas/síntese química , Amidinas/química , Amidinas/farmacologia , Animais , Células CHO , Cricetinae , Humanos , Naltrexona/química , Naltrexona/farmacologia , Antagonistas de Entorpecentes/química , Antagonistas de Entorpecentes/farmacologia , Ensaio Radioligante , Receptores Opioides delta/metabolismo , Receptores Opioides kappa/metabolismo , Ureia/análogos & derivados , Ureia/síntese química , Ureia/química , Ureia/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA